# Atherogenic Dyslipidemia in Children and Adolescents: Current Evidence, Clinical Challenges, and Future Perspectives

**Authors:** Marco Giussani, Manuela Casula, Antonina Orlando, Gianfranco Parati, Simonetta Genovesi

PMC · DOI: 10.3390/jcdd13020089 · 2026-02-11

## TL;DR

This paper reviews atherogenic dyslipidemia in children, focusing on causes, diagnosis, and treatment differences compared to adults.

## Contribution

The paper provides a clinically focused summary of current evidence on dyslipidemia in children and adolescents.

## Key findings

- Atherogenic dyslipidemia in children can lead to early vascular damage.
- Genetic forms of dyslipidemia often require drug treatment, while lifestyle-related forms may only need dietary changes.
- The review highlights diagnostic criteria and treatment options specific to children.

## Abstract

Atherogenic dyslipidemia is a condition characterized by high lipid levels that promote the development of atherosclerosis. While the clinical manifestations of atherosclerosis typically manifest in adulthood, early vascular damage can be identified in children and adolescents. Dyslipidemia is not uncommon in childhood and adolescence, and its development depends on the interaction between genetic and environmental factors. Forms caused by genetic defects tend to manifest earlier and usually require drug treatment. Forms caused by unhealthy lifestyles and eating habits tend to manifest later and often only require dietary and behavioural treatment. The review describes the most common primary forms, diagnostic criteria and treatment options, both pharmacological and non-pharmacological, emphasizing the differences and specificities of dyslipidemia in children compared to adults. The review’s objective is also to provide a clinically focused summary of the current evidence on atherogenic dyslipidemia in children and adolescents.

## Linked entities

- **Diseases:** atherosclerosis (MONDO:0005311)

## Full-text entities

- **Genes:** ABCG8 (ATP binding cassette subfamily G member 8) [NCBI Gene 64241] {aka GBD4, STSL, STSL1}, HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) [NCBI Gene 3156] {aka LDLCQ3, LGMDR28, MYPLG}, APOA5 (apolipoprotein A5) [NCBI Gene 116519] {aka APOAV, RAP3}, LMF1 (lipase maturation factor 1) [NCBI Gene 64788] {aka C16orf26, HMFN1876, JFP11, TMEM112, TMEM112A}, APOA1 (apolipoprotein A1) [NCBI Gene 335] {aka AMYLD3, HPALP2, apo(a)}, GPIHBP1 (glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1) [NCBI Gene 338328] {aka GPI-HBP1, HYPL1D}, FLNB (filamin B) [NCBI Gene 2317] {aka ABP-278, ABP-280, FH1, FLN-B, FLN1L, LRS1}, LPA (lipoprotein(a)) [NCBI Gene 4018] {aka AK38, APOA, LP}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, ABCG5 (ATP binding cassette subfamily G member 5) [NCBI Gene 64240] {aka STSL, STSL2}, PCSK9 (proprotein convertase subtilisin/kexin type 9) [NCBI Gene 255738] {aka FH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1}, LIPA (lipase A, lysosomal acid type) [NCBI Gene 3988] {aka CESD, LAL}, APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, APOC2 (apolipoprotein C2) [NCBI Gene 344] {aka APO-CII, APOC-II}, LDLRAP1 (low density lipoprotein receptor adaptor protein 1) [NCBI Gene 26119] {aka ARH, ARH1, ARH2, FHCB1, FHCB2, FHCL4}, ABCA1 (ATP binding cassette subfamily A member 1) [NCBI Gene 19] {aka ABC-1, ABC1, CERP, HDLCQTL13, HDLDT1, HPALP1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, ANGPTL3 (angiopoietin like 3) [NCBI Gene 27329] {aka ANG-5, ANGPT5, ANL3, FHBL2}, LPL (lipoprotein lipase) [NCBI Gene 4023] {aka HDLCQ11, LIPD}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, APOC3 (apolipoprotein C3) [NCBI Gene 345] {aka APOCIII, Apo-C3, ApoC-3}, LCAT (lecithin-cholesterol acyltransferase) [NCBI Gene 3931]
- **Diseases:** hyperinsulinemia (MESH:D006946), high blood pressure (MESH:D006973), Atherosclerosis (MESH:D050197), hepatomegaly (MESH:D006529), rhabdomyolysis (MESH:D012206), Hypolipidemias (MESH:C565732), toxicity (MESH:D064420), FH (MESH:D006938), vascular damage (MESH:D057772), insulin resistance (MESH:D007333), CHILD-2 (MESH:C562515), CHILD-1 (OMIM:603663), cardiovascular disease (MESH:D002318), ischemic stroke (MESH:D002544), thrombocytopenia (MESH:D013921), liver failure (MESH:D017093), heart disease (MESH:D006331), myalgia (MESH:D063806), Hypercholesterolemia (MESH:D006937), LAL-D (MESH:C531854), Monogenic or Familial Chylomicronemia (MESH:D008072), Hypertriglyceridemia (MESH:D015228), lipid (MESH:D011017), Atherogenic dyslipidemia (MESH:D050171), alcohol abuse (MESH:D000437), tendon xanthomas (MESH:D014973), chronic inflammation (MESH:D007249), HoFH (MESH:D000090542), injury to (MESH:D014947), metabolic syndrome (MESH:D024821), disorders of carbohydrate metabolism (MESH:D002239), cirrhosis (MESH:D005355), FCS (MESH:D056685), abdominal pain (MESH:D015746), lysosomal storage disorder (MESH:D016464), acute pancreatitis (MESH:D010195), non-alcoholic fatty liver disease (MESH:D065626), hepatosplenomegaly (MESH:C535727), endothelial dysfunction (MESH:D014652), diabetes (MESH:D003920), Tangier disease (MESH:D013631), overweight (MESH:D050177), steatohepatitis (MESH:D005234), obese (MESH:D009765), Hypoalphalipoproteinemia (MESH:D052456), nausea (MESH:D009325), vomiting (MESH:D014839), hemolysis (MESH:D006461), Genetic defects (MESH:D030342), Combined familial hyperlipidemia (MESH:D006950)
- **Chemicals:** Cholestyramine (MESH:D002792), olezearsen (-), Bile Acid (MESH:D001647), cholesterol esters (MESH:D002788), fatty acids (MESH:D005227), carbohydrates (MESH:D002241), Bempedoic Acid (MESH:C581236), Fibrates (MESH:D058607), Lipid (MESH:D008055), docosahexaenoic acid (MESH:D004281), sterols (MESH:D013261), polyphenols (MESH:D059808), fructose (MESH:D005632), steroid hormones (MESH:D013256), glucose (MESH:D005947), folates (MESH:D005492), oleic acid (MESH:D019301), alcohol (MESH:D000438), Ezetimibe (MESH:D000069438), sugars (MESH:D000073893), Lomitapide (MESH:C473731), evolocumab (MESH:C577155), TGs (MESH:C026285), fat (MESH:D005223), Evinacumab (MESH:C000621590), simple sugars (MESH:D009005), TG (MESH:D014280), alirocumab (MESH:C571059), C (MESH:D002244), phytosterols (MESH:D010840), omega-3 fatty acids (MESH:D015525), uric acid (MESH:D014527), free fatty acids (MESH:D005230), eicosapentaenoic acid (MESH:D015118), water (MESH:D014867), phospholipids (MESH:D010743), carotenoids (MESH:D002338), Cholesterol (MESH:D002784), volanesorsen (MESH:C000593612), oligonucleotides (MESH:D009841)
- **Species:** Homo sapiens (human, species) [taxon 9606], Linum usitatissimum (flax, species) [taxon 4006]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942339/full.md

---
Source: https://tomesphere.com/paper/PMC12942339